Results 1 to 10 of about 27,357 (215)

Pharmaceutical co-crystals of posaconazole for improvement of physicochemical properties [PDF]

Brazilian Journal of Pharmaceutical Sciences, 2022
Posaconazole exerts an extended spectrum of antifungal activity against various strains of clinically relevant moulds and yeasts. In recent years, antifungal triazole posaconazole has become increasingly important for the prophylaxis and treatment of ...
Monika Nijhawan, Monika Godugu, Trapti Saxena, Talat Farheen, Kanchan Dwivedi   +4 more
doaj   +2 more sources

Advancing posaconazole quantification analysis with a new reverse-phase HPLC method in its bulk and marketed dosage form [version 2; peer review: 2 approved]

F1000Research, 2023
Introduction: Posaconazole is a widely used antifungal drug, and its accurate quantification is essential for quality control and assessment of its pharmaceutical products.
Srinivas Hebbar, Anup Naha, Abhishek Chaturvedi, Usha Rani, Annamalai Rama, Induja Govindan   +5 more
doaj   +2 more sources

Posaconazole [PDF]

Reactions Weekly, 2020
A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme.
semanticscholar   +6 more sources

Synergistic Interaction of Caspofungin Combined with Posaconazole against FKS Wild-Type and Mutant Candida auris Planktonic Cells and Biofilms

Antibiotics, 2022
Candida auris is a potential multidrug-resistant pathogen able to cause biofilm-associated outbreaks, where frequently indwelling devices are the source of infections.
Noémi Balla, Fruzsina Kovács, Bence Balázs, Andrew M. Borman, Aliz Bozó, Ágnes Jakab, Zoltán Tóth, Ola Kobaissi, László Majoros, Renátó Kovács   +9 more
doaj   +2 more sources

Enhanced antifungal activity of posaconazole against Candida auris by HIV protease inhibitors, atazanavir and saquinavir

Scientific Reports
The increasing incidence and dissemination of multidrug-resistant Candida auris represents a serious global threat. The emergence of pan-resistant C. auris exhibiting resistance to all three classes of antifungals magnifies the need for novel therapeutic
Yehia Elgammal, Ehab A. Salama, Mohamed N. Seleem   +2 more
doaj   +2 more sources

A Review of Population Pharmacokinetic Models of Posaconazole

Drug Design, Development and Therapy, 2022
Qin Ding,1,* Shuqi Huang,1,* Zexu Sun,2 Kaifeng Chen,1 Xin Li,3 Qi Pei1 1Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 2Xiangya School of Pharmaceutical Sciences, Central South
Ding Q, Huang S, Sun Z, Chen K, Li X, Pei Q   +5 more
doaj   +2 more sources

Real-Life Use of Posaconazole in Clinical Practice for Onco-Hematological Children: A National Survey by AIEOP Infectious Diseases Working Group [PDF]

Journal of Fungi
Background: Posaconazole is an antifungal medication used to treat invasive fungal infections (IFI) in pediatric onco-hematological patients. Its approval for pediatric use was recent, and limitations still apply.
Lorenzo Chiusaroli, Manuela Spadea, Cecilia Liberati, Maria Grazia Petris, Antonio Grasso, Francesco Baccelli, Maria Vittoria Micheletti, Pietro Gasperini, Maria Rosaria D’Amico, Katia Perruccio, Angelica Barone, Daniela Onofrillo, Paola Muggeo, Maura Faraci, Simona Rinieri, Ilaria Liguoro, Antonella Colombini, Francesca Trevisan, Nagua Giurici, Gianluca Boscarol, Letizia Pomponia Brescia, Alessia Pancaldi, Francesca Compagno, Alessandra Biffi, Daniele Donà, Simone Cesaro   +25 more
doaj   +2 more sources

Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats

Drug Design, Development and Therapy, 2021
Suili Yang,1,* Xiaoshan Zhang,2,3,* Yuzhen Wang,2,3 Congcong Wen,4 Chenxiang Wang,3 Ziye Zhou,5 Guanyang Lin3 1Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China ...
Yang S, Zhang X, Wang Y, Wen C, Wang C, Zhou Z, Lin G   +6 more
doaj   +2 more sources

Plasma Concentrations of Prophylactic Posaconazole and Risk Factors for Subtherapeutic Exposure in Taiwanese Patients with Hematologic Malignancies [PDF]

Drug Design, Development and Therapy
Hsing-Yu Lin,1,* Shu-Chen Hu,2,* Tsung-Yu Pai,1 Fang-Ju Lin,1,3,4 Chien-Chih Wu1,3 1Department of Pharmacy, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; 2Department of Pharmacy ...
Lin HY, Hu SC, Pai TY, Lin FJ, Wu CC
doaj   +2 more sources

Posaconazole

Journal of Postgraduate Medicine, 2010
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal ...
Bhattacharya, M., Rajeshwari, K., Dhingra, B.   +2 more
  +5 more sources